Bachem Holding AG Class B · SIX:BANB

Bachem Holding AG Class B — FY2023 Earnings Presentation

30 slides from Bachem Holding AG Class B's earnings presentation, Mar 7, 2024

  1. Slide 1: Bachem FY Results 2023

    Slide 1: Bachem FY Results 2023

    Date | March 7, 2024 Location | Zurich / Zoom Call Name | Thomas Meier, Alain Schaffter

  2. Slide 2: Questions and call recording information

    Slide 2: Questions and call recording information

    At the end of the presentation there will be time for questions. Write to us in the Q&A section anytime. This call will be recorded and playback will be posted on bachem.com. 2 Bachem FY Results 2023

  3. Slide 3: Speakers

    Slide 3: Speakers

    SPEAKERS ie j aS Thomas Meier Alain Schaffter Daniel Grotzky (Moderator) CEO CFO Head Group Communication BACHEM = Bn

  4. Slide 4: Agenda

    Slide 4: Agenda

    Full Year Results 2023 – Thomas Meier 01 Financial Review 2023 – Alain Schaffter 02 03 Outlook 2024 – Thomas Meier 04 Q & A - all 4 Bachem FY Results 2023

  5. Slide 5: Thomas Meier

    Slide 5: Thomas Meier

    Thomas Meier 5 Bachem FY Results 2023

  6. Slide 6: Full Year 2023 highlights

    Slide 6: Full Year 2023 highlights

    Sales Profitability • Sales of CHF 577.3m (+8.6%). • EBITDA CHF 166.7m / margin 28.9% • Local currency increase +12.8%. (29.1% adjusted). • Strong H2/23 with CHF 337.5m • Local currencies EBITDA margin 30.5%. (+13.7% against H2/22). • Proposal to increase dividend to CHF 0.80 per • Key drivers CMC d

  7. Slide 7: Sales by business segment

    Slide 7: Sales by business segment

    Change in in CHF million 2023 Change in CHF Sales share local currency Research & Specialties 40.8 – 13.5% – 10.4% 7.1% CMC Development 227.5 + 22.4% + 27.7% 39.4% Commercial API 309.0 + 3.4% + 7.1% 53.5% Total sales 577.3 + 8.6% + 12.8% 100.0% 7 Bachem FY Results 2023

  8. Slide 8: Sales drivers: tailwinds and headwinds

    Slide 8: Sales drivers: tailwinds and headwinds

    Commercial API: • Originator peptides, including first sales from strategic long-term customers. • Generic peptides. CMC development: Tailwinds • Strong peptide project landscape. • Strong oligonucleotide development growth. +8.6% Commercial API: • Lower commercial oligonucleotide sales. Headwinds •

  9. Slide 9: H1 and H2 sales development

    Slide 9: H1 and H2 sales development

    +13.7% 338 297 264 239 235 240 225 179 177 135 2019 2020 2021 2022 2023 H1 sales H2 sales 9 Bachem FY Results 2023

  10. Slide 10: Sales distribution by customer tiers

    Slide 10: Sales distribution by customer tiers

    Sales distribution by customer tiers in % of sales 100.0% 90.0% 80.0% 70.0% 60.0% 50.0% 40.0% Top 10 customers 30.0% c. 63% of 20.0% sales 10.0% 0.0% 2019 2020 2021 2022 2023 Top 5 Top 6-10 Top 11-15 Other 10 Bachem FY Results 2023

  11. Slide 11: NCE pipeline with 162 projects

    Slide 11: NCE pipeline with 162 projects

    • NCE pipeline with 162 projects. No. of No. of Phase projects projects • Focused due to biotech funding end 2023 end 2022 environment. Preclinical 74 80 • Therapy areas include metabolic diseases, oncology, neuroscience, Phase 1 40 39 inflammatory diseases, infectious Phase 2 34 44 diseases and oth

  12. Slide 12: Sustainability: EcoVadis Gold rating, CDP disclosure

    Slide 12: Sustainability: EcoVadis Gold rating, CDP disclosure

    Energy, Hazardous Waste and Water per employee from 2020 base figures 100 95 • EcoVadis “Gold Rating” in 2023. 90 85 • Greenhouse gas disclosure via Carbon Disclosure Project (CDP) with a “B” 80 ranking. 75 70 • Sustainable Procurement: 75% of high-medium sustainability risk partners have completed

  13. Slide 13: Building K and Bubendorf

    Slide 13: Building K and Bubendorf

    Building K • Shift from medium-size multi-functional TIDES equipment to large scale equipment during construction phase. • First manufacturing lines scheduled for 2nd half 2024. Bubendorf • New equipment in existing buildings to support strategic customer projects. • 24/7 shift system implemented. 1

  14. Slide 14: Global network and Sisslerfeld

    Slide 14: Global network and Sisslerfeld

    Global network • Vista: additional capabilities for large-scale customers planned. • Vionnaz: production returning in staggered approach. Sisslerfeld • 2nd portion of land purchase in H1/2023. • Legal entity “Bachem Sisslerfeld AG” established. • Site development plan submitted to authorities. 14 Ba

  15. Slide 15: Alain Schaffter

    Slide 15: Alain Schaffter

    Alain Schaffter 15 Bachem FY Results 2023

  16. Slide 16: Key financial figures 2023

    Slide 16: Key financial figures 2023

    Change in 2023 2022 Change CHF local currency Sales (in CHF million) 577.3 531.7 + 8.6% + 12.8% EBITDA (in CHF million) 166.7 160.5 + 3.9% + 13.9% in relation to sales 28.9% 30.2% EBIT (in CHF million) 129.4 127.2 + 1.7% + 14.1% in relation to sales 22.4% 23.9% Net income (in CHF million) 111.9 100.

  17. Slide 17: EBITDA margin bridge

    Slide 17: EBITDA margin bridge

    -130 bps 30.2 -1.4 0.4 -0.6 28.9 0.2 EBITDA COGS M&S R&D G&A / EBITDA margin other margin 2022 income 2023 17 Bachem FY Results 2023

  18. Slide 18: Operating cash flow and net change in cash

    Slide 18: Operating cash flow and net change in cash

    Impacted by non-current prepayments from customers of CHF 145.6m. • Capex cash-out -268.4 • Sale of securities +94.9 169.7% -63.2 249.9 313.0 -24.0 • Capital increase +105.9 • Dividend -56.2 -38.1 249.9 -1.1 -170.8 -1.5 126.3 92.6 48.7 Operating Operating Operating Change in Change in Change in Oper

  19. Slide 19: Balance sheet and liquidity

    Slide 19: Balance sheet and liquidity

    676.8 595.6 157.7 31.5 1 383.9 1 682.9 237.0 140.8 214.2 (15%) 362.4 (22%) 378.5 327.6 1320.5 1169.7 (78%) (85%) Liabilities -0.3 -0.2 Equity Dec. 31, 2022 Dec. 31, 2023 Dec. 31, 2022 Dec. 31, 2023 Cash and cash equivalents Securities Current financial liabilities Net working capital 19 Bachem FY Re

  20. Slide 20: Capex and depreciation

    Slide 20: Capex and depreciation

    269.0 142.6 130.7 76.4 46.6 28.4 33.3 32.7 25.9 24.9 37.4 10.4 26.0 26.8 19.0 2019 2020 2021 2022 2023 CAPEX in CHF million Depreciation in CHF million CAPEX in % of sales 20 Bachem FY Results 2023

  21. Slide 21: Thomas Meier

    Slide 21: Thomas Meier

    Thomas Meier 21 Bachem FY Results 2023

  22. Slide 22: Oligonucleotide development and commercial update

    Slide 22: Oligonucleotide development and commercial update

    • Bachem footprint across technologies: siRNA, ASOs incl. PMOs; commercial and development presence. • Significant expansion of oligonucleotide development sales balances out reduced oligo commercial sales. • Long-term partnerships progressing well. • Industry-wide > 100 oligonucleotide projects in

  23. Slide 23: Disruption in healthcare and TIDES industry

    Slide 23: Disruption in healthcare and TIDES industry

    Disruption in healthcare Disruption in TIDES industry • Incretins targeting diabetes & obesity promise • Biopharma capacity expansion projects and disruptive change in patient outcomes. heightened activity, e.g.: • Growing body of evidence on reduction of co- • USD 6 bn. Novo Nordisk announcement. m

  24. Slide 24: Market environment, Bachem advantages and priorities

    Slide 24: Market environment, Bachem advantages and priorities

    Favorable Bachem-specific Bachem priorities market environment advantage in 2024 and beyond • Incretins (e.g. GLP-1) drive • Specialized in chemical • Execute on capacity cross-industry scale-up need. synthesis as technology expansion plans. platform. • Peptides in clinical • Ongoing transformation

  25. Slide 25: CMO and CDMO growth opportunities

    Slide 25: CMO and CDMO growth opportunities

    Large-scale Established global leader opportunity for continue growth accelerated growth & remain competitive CMO CDMO «Trailblazing» CDMO “Best of both worlds”: First-mover advantage & Cost-effective manufacturing, Sponsor and Bachem develop access for sponsors to new e.g. for sponsors with existin

  26. Slide 26: Key focus: execution on large-scale capacity expansion

    Slide 26: Key focus: execution on large-scale capacity expansion

    Key focus to realize growth: Execution on large-scale capacity expansion ✓ Long-term large-scale CMO contracts in place (c. 75% of required growth till 2025) ✓ Continue successful track record for CDMO business ✓ Leverage leadership in TIDES chemical synthesis as a technology platform 2023: 2026: 20

  27. Slide 27: Outlook 2024 and 2026

    Slide 27: Outlook 2024 and 2026

    2024 Full Year 2026 Sales Sales Mid-high single-digit growth in > CHF 1.0 bn. local currencies. Profitability Profitability Stable EBITDA margin EBITDA ahead of 30%. compared to prior year in local currencies. 27 Bachem FY Results 2023

  28. Slide 28: Q&A

    Slide 28: Q&A

    All 28 Bachem FY Results 2023

  29. Slide 29: Questions? Send an e-mail

    Slide 29: Questions? Send an e-mail

    Question? Send an e-mail to… ir@bachem.com media@bachem.com 29 Bachem FY Results 2023

  30. Slide 30: Forward-looking statements

    Slide 30: Forward-looking statements

    This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str

Source: Internet Archive copy of bachem.com

More decks from Bachem Holding AG Class B

All 14 Bachem Holding AG Class B decks